A facile method for late stage diversification of lead molecules for the M1 PAM program using biosynthesis is described. Liver microsomes from several species are screened to identify a high turnover system. Subsequent incubations using less than 1 mg of substrate generate nanomole quantities of drug metabolites that are purified, characterized by microcryoprobe NMR spectroscopy, and quantified to known concentrations to enable rapid biology testing. The late-stage diversification of lead compounds provides rapid SAR feedback to the medicinal chemistry design cycle.
Keywords: Biosynthesis; Late-stage diversification; M1 positive allosteric modulator (PAM) program; Medicinal chemistry design cycle.
Copyright © 2018 Elsevier Ltd. All rights reserved.